In an effort to guarantee "the ongoing quality, safety, nutritional adequacy, and resilience of the domestic infant formula ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
23h
HHS Secretary Robert F. Kennedy Jr. discussed a new initiative aimed at improving the safety and nutritional value of baby ...
Q4 2024 Management View CEO Eef Schimmelpennink highlighted 2024 as a transformative year, marked by significant milestones, including the completion of the Phase 3 CLARITY study, submission and ...
Q4 2024 Management View CEO Linda Marban highlighted the acceptance by the FDA of Capricor's Biologics License Application (BLA) for deramiocel, targeting treatment of Duchenne muscular dystrophy (DMD ...
The FDA and HHS announced "Operation Stork Speed" Tuesday, which aims to increase testing for heavy metals and other ...
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025Upon FDA approval, ...
The effort, dubbed “Operation Stork Speed,” aims to ensure “quality, safety, nutritional adequacy, and resilience” of infant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback